{"schema_version":"secwatch.filing_event.v1","accession":"0001121702-23-000027","form_type":"8-K","ticker":null,"cik":"0001121702","company_name":"YIELD10 BIOSCIENCE, INC.","filed_at":"2023-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.995461+00:00","generated_at":"2026-06-14T19:22:52.605466+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Yield10 Bioscience gets Nasdaq deficiency letter for equity of $1.143M, below $2.5M minimum","bullets":["Received Nasdaq deficiency letter on May 18, 2023 for failing minimum stockholders' equity requirement.","Stockholders' equity reported at $1,143,000 as of March 31, 2023, well below the $2.5M threshold.","Must submit a compliance plan by July 3, 2023; Nasdaq may grant up to 180-day extension if plan accepted.","No immediate effect on listing; company can appeal a rejected plan to Nasdaq Hearings Panel.","Company intends to submit plan and explore options but cannot assure regaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001121702-23-000027","json":"https://secwatch.observer/filing/0001121702-23-000027.json","markdown":"https://secwatch.observer/filing/0001121702-23-000027.md","text":"https://secwatch.observer/filing/0001121702-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1121702/000112170223000027/0001121702-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1121702/000112170223000027/yten-20230518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T19:22:52.605466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04c8a6f45fe01dec0aef03cae4eeecd89eb21a42","claim":"YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 18, 2023, Yield10 Bioscience, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the quarter ended Mar","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1121702/000112170223000027/0001121702-23-000027-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}